trending Market Intelligence /marketintelligence/en/news-insights/trending/2Dq8Zh82ohOSneAmTSyvHw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Natco launches generic to compete with Roche's influenza treatment

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Natco launches generic to compete with Roche's influenza treatment

India's Natco Pharma Ltd. launched a generic version of Roche Holding Ltd.'s Tamiflu in the U.S.

Alvogen partnered with Natco to market the influenza treatment, which is available in three doses.

Roche's Tamiflu had U.S. sales of approximately $403 million in the 12 months ending December 2015, according to IMS Health.